Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT19 CAR-T Cells for CD19+ Hematological Malignancies
NCT04796688Phase 1Unknown
- Start
- Mar 2021
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 1, open-label trial in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and B cell lymphoma. Primary endpoint: Treatment-related Adverse Events at 2 years. Status: unknown.
02
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)B cell lymphoma
Beyond the preview
Go deeper on NCT04796688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04796688.